Alzheimer y demencia Senil como enfermedades prevenibles
Keywords:
Alzheimer’s disease, Senile dementia, Prevention, Treatment, Risk factor.Abstract
Alzheimer’s disease (AD) and senile dementia are the main causes of cognitive impairment
in the elderly population, with distinct characteristics and treatments. AD is a progressive
neurodegenerative disorder, where the accumulation of beta-amyloid plaques and tau protein
tangles in the brain leads to neuronal loss, affecting memory and the ability to perform daily
activities. Senile dementia, on the other hand, is a broader term that encompasses several forms
of age-related dementia, Alzheimer’s being the most common. AD is responsible for up to 70% of
dementia cases worldwide, with more than 50 million people affected, a figure that increases with
age, particularly after the age of 65.
In Latin America, the prevalence of dementia is high and continues to increase due to population
aging and the presence of risk factors such as hypertension, diabetes, obesity and sedentary
lifestyle. The clinical symptoms of AD and senile dementia begin with memory problems,
disorientation, personality changes and difficulties in performing complex tasks. As the disease
progresses, these symptoms worsen, leading to increased dependence of the patient to perform
basic activities, along with behavioral disorders and severe dementia. In terms of treatment,
progress has been limited. The aim of this review is to describe AD and senile dementia as a disease.
References
Chatterjee K, Mazumder PM, Banerjee S. Vitamin K2 protects against aluminium chloride-mediated neurodegeneration. Inflammopharmacology. 2023;31(5).
Schnieder M, Viehmeister B. Polypharmacy in patients with dementia. Innere Medizin (Germany). 2023.
Schnieder M, Viehmeister B. Polypharmazie bei Demenzerkrankten. Die Innere Medizin. 2024;65(1).
Prajjwal P, Inban P, Sai VP, Shiny KS, Lam JR, John J, et al. The effects of the interplay between vitamins, antibiotics, and gut microbiota on the pathogenesis and progression of dementia: A systematic review and meta-analysis. Vol. 7, Health Science Reports. 2024.
Zahr N. Alcohol Use Disorder and Dementia: A Review. Alcohol Research: Current Reviews. 2024;44(1).
Farina FR, Regan J, Marquez M, An H, O’Loughlin P, Pavithra P, et al. Reducing fear and avoidance of memory loss improves mood and social engagement in community-based older adults: a randomized trial. BMC Geriatrics. 2023 Nov 29;23(1):786.
Oliveira Monteiro e Pereira de Almeida MP, Valle Pedroso R, Mantellatto Grigoli M, Vicente Silva T, Manzine PR, Cominetti MR. ADAM10 as a biomarker for Alzheimer’s disease: A systematic review. Revue Neurologique. 2024 Jan;180(1–2):1–11.
Ito T, Degawa T, Okumura N. Brazilian green propolis prevent Alzheimer’s disease-like cognitive impairment induced by amyloid beta in mice. BMC Complementary Medicine and Therapies. 2023;23(1).
Imbimbo BP, Watling M. What have we learned from past failures of investigational drugs for Alzheimer’s disease? Expert Opinion on Investigational Drugs. 2021 Dec 2;30(12):1175–82.
Yadav S, Aggarwal P, Khan F, Khodve G, Padhy DS, Yadav P, et al. β-sitosterol Protects against Aluminium Chloride-mediated Neurotoxicity. Current Alzheimer Research. 2023;20(1).
Ostapiuk A, Urbanska EM. Kynurenic acid in neurodegenerative disorders—unique neuroprotection or double-edged sword? Vol. 28, CNS Neuroscience and Therapeutics. 2022.
Lai M, Jeon YH, McKenzie H, Withall A. Journey to Diagnosis of Young-Onset Dementia: A Qualitative Study of People with Young-Onset Dementia and their Family Caregivers in Australia. Dementia. 2023;22(5).
Wallace L, Brayne C, Rockwood K, Fleming J, Theou O. Fragilidad y neuropatología en relación con el estado de demencia: el estudio de cohorte de mayores de 75 años de la ciudad de Cambridge. Psicogeriatria Internacional. 2021;33:1035–43.
Selbæk-Tungevåg S, Selbæk G, Playa B, Myrstad C, Livingston G, Lydersen S, et al. Insomnio y riesgo de demencia en un gran estudio poblacional con un seguimiento de 11 años: el estudio HUNT. Journal of Sleep Research. 2023 Jan 23;
Desai U, Kirson NY, Ye W, Mehta NR, Wen J, Andrews JS. Trends in health service use and potentially avoidable hospitalizations before Alzheimer’s disease diagnosis: A matched, retrospective study of US Medicare beneficiaries. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring. 2019;11.
Iqubal A, Iqubal MK, Fazal SA, Pottoo FH, Haque SE. Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer’s Disease. Current Molecular Pharmacology. 2021;15(1).
Zakharova N v., Bugrova AE, Indeykina MI, Fedorova YB, Kolykhalov I v., Gavrilova SI, et al. Proteomic Markers and Early Prediction of Alzheimer’s Disease. Vol. 87, Biochemistry (Moscow). 2022.
Yang L, Wu C, Li Y, Dong Y, Wu CYC, Lee RHC, et al. Long-term exercise pre-training attenuates Alzheimer’s disease–related pathology in a transgenic rat model of Alzheimer’s disease. GeroScience. 2022;44(3).
Lai F, Mhatre PG, Yang Y, Wang MC, Schupf N, Rosas HD. Sex differences in risk of Alzheimer’s disease in adults with Down syndrome. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring. 2020;12(1).
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody (Alzheimer’s Research & Therapy, (2021), 13, 1, (80), 10.1186/s13195-021-00813-8). Vol. 14, Alzheimer’s Research and Therapy. 2022.
Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer’s Research and Therapy. 2021;13(1).
Kurowska A, Ziemichód W, Herbet M, Piątkowska-Chmiel I. The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases. Vol. 15, Nutrients. 2023.
Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration. Brain. 2023;146(3).
Correction: Brain-derived tau: A novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration (Brain (2023) 146 (1152-1165).
Paumier A, Boisseau S, Jacquier-Sarlin M, Pernet-Gallay K, Buisson A, Albrieux M. Astrocyte-neuron interplay is critical for Alzheimer’s disease pathogenesis and is rescued by TRPA1 channel blockade. Brain. 2022;145(1).
McGurran H, Glenn JM, Madero EN, Bott NT. Prevention and Treatment of Alzheimer’s Disease: Biological Mechanisms of Exercise. Vol. 69, Journal of Alzheimer’s Disease. 2019.
Guzman-Martinez L, Calfío C, Farias GA, Vilches C, Prieto R, MacCioni RB. New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer’s Disease. Vol. 82, Journal of Alzheimer’s Disease. 2021.
Townsend R, Fairley A, Gregory S, Ritchie C, Stevenson E, Shannon OM. Nutrición para la prevención de la demencia: una actualización de vanguardia para médicos. Age and Ageing. Mayo de 2024;53(Suplemento_2):ii30-8.
Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C, Fox NC. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024 Aug 10;404(10452):572.
Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J. El estudio finlandés de intervención geriátrica para prevenir el deterioro cognitivo y la discapacidad (FINGER): diseño del estudio y progreso. Alzheimer y demencia. 1 de noviembre de 2013; 9 (6): 657-65.
Downloads
Published
Versions
- 2025-11-17 (3)
- 2025-11-17 (2)
- 2025-05-01 (1)
How to Cite
Issue
Section
License
Copyright (c) 2024 Scientific and Eduaction Medical JournalAtribución – No comercial – Compartir igual: Esta licencia permite a otros distribuir, remezclar, retocar, y crear a partir de tu obra de modo no comercial, siempre y cuando te den crédito y licencien sus nuevas creaciones bajo las mismas condiciones.
Attribution-NonCommercial-ShareAlike 4.0 International
